Sanofi's CEO is under pressure to tell investors how much more he will spend on research and development (R&D) and what the likely pay-offs will be, as he seeks to boost a pipeline of future drugs ...

Limited pipeline catalysts until 2025 mean a "show me" story status. Higher R&D costs and uncertainty for the future. A new spin-off in the consumer division with no 2025 profitability targets. San...

Sanofi plans to file for U.S. approval of wider use of its anti-inflammatory drug Dupixent against "smoker's lung", also known as COPD, after a second large trial showed significant benefits.

The mother of two autistic children in France has lodged a legal complaint for endangering life after she suspected she was exposed to airborne emissions from Sanofi's Depakine epilepsy drug plant,...

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

French prosecutors have opened a preliminary investigation into multinational pharmaceutical company Sanofi over possible market manipulation.

Sanofi's third-quarter results weren't great, and the company announced a business separation. The biotech will lower its operating income margin target for 2025, which scared off many investors.

Sanofi (SNY) shares are trending higher after plummeting last Friday, after the pharmaceutical company missed third-quarter earnings expectations, losing over $21 billion in market value. Sanofi an...

Sanofi (NASDAQ:SNY ) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Eva Schaefer-Jansen - Head of Investor Relations Paul Hudson - Chief Executive Officer Jean-Ba...

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.

Sanofi (NYSE: SNY ) stock fell about 15% overnight after it predicted slower profit growth next year. The French drug company also said it will follow rivals and spinoff its consumer health business.

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, spin off of its consumer health care business, growth outlook, and more.

Shares of French drugmaker Sanofi fell as much as 16% on Friday after after hiking its research-and-development expense guidance as well as its expectations for taxes.

Sanofi on Friday mapped out a potential separate listing of its consumer healthcare business from the fourth quarter of next year, as it plans to shore up new drug development spending at its core ...

Sanofi SA, the French pharmaceutical company, has announced plans to potentially separate its consumer healthcare division by listing it on the capital markets by the end of next year. If the IPO o...